菜单

CRO Services

Drug Development Expertise Empowering Research Services for Biologics

 

T-cell receptor (TCR) therapies hold tremendous potential to treat cancer, autoimmune, and infectious diseases, but natural TCRs often show low affinity for their targets. WuXi Biologics’ advanced TCR optimization platform overcomes this challenge combining dvanced phage display, targeted mutagenesis, and HTP production and screening.

 

Download the poster to discover:

 

  • Multi-site mutant library construction for diverse, high-quality TCR variants using advanced phage display
  • High-throughput screening and SPR koff ranking to identify binders with enhanced specificity and stability
  • Case Study: HTP TCR production with 0.85 g/L yield and >92% purity
  • Up to 14,347-fold improvement in TCR affinity for target antigens versus non-targets

 

 

 

Enter your information to download the poster